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Objective: To study in parallel the outflow of the sympathetic nervous system (SNS) and the hypothalamic-
pituitary adrenal (HPA) axis tone in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Methods: 32 patients with SLE, 62 with RA, and 65 healthy subjects (HS) were included. To measure the
tone of the HPA axis, plasma ACTH and serum cortisol were determined. Serum neuropeptide Y (NPY) was
used to evaluate the sympathetic outflow.
Results: Patients with SLE had increased NPY levels in comparison with HS, irrespective of prior
prednisolone treatment (p,0.001). For patients with RA, only those with prednisolone treatment had
increased NPY levels in comparison with HS (p = 0.016). Daily prednisolone dose correlated positively
with serum NPY in RA (RRank = 0.356, p = 0.039). In contrast, plasma ACTH levels were generally
decreased significantly in comparison with HS in SLE with prednisolone, and in RA with/without
prednisolone. Similarly, serum cortisol levels were also decreased in SLE with/without prednisolone, and
in RA with prednisolone. The NPY/ACTH ratio was increased in SLE and RA, irrespective of prior
prednisolone treatment. The NPY/cortisol ratio was increased in SLE with/without prednisolone, and in RA
with prednisolone. Twelve weeks’ anti-TNF antibody treatment with adalimumab did not decrease NPY
levels in RA, irrespective of prednisolone treatment.
Conclusions: An increased outflow of the SNS was shown and a decreased tone of the HPA axis in patients
with SLE and RA. Low levels of cortisol in relation to SNS neurotransmitters may be proinflammatory
because cooperative anti-inflammatory coupling of the two endogenous response axes is missing.
D
uring acute inflammation in humans and animals,
activation of the hypothalamic-pituitary adrenal (HPA)
axis and the sympathetic nervous system (SNS) is
seen.1–6 In chronic inflammatory diseases such as systemic
lupus erythematosus (SLE) or rheumatoid arthritis (RA) the
HPA axis alters markedly : (a) secretion of adrenocortico-
tropic hormone (ACTH) relative to circulating cytokines is
inadequate7; (b) patients have inappropriately low sponta-
neous and stimulated cortisol secretion in relation to
inflammation7–11; (c) adrenal androgens decrease dramati-
cally.11–15 The reasons for these changes are only partly
understood, but striking changes on all levels of the HPA axis
seem to have a role. For example, during repetitive admin-
istration of interleukin (IL) 6 over 3 weeks, the stimulatory
capacity of IL6 on the central level is normally lost, but
stimulation of the adrenal glands remains relatively stable.4 5
At this point, the question arises as to what happens with
the SNS in chronic inflammatory diseases. Some studies have
indicated that patients with chronic inflammatory diseases
have an increased activity of the SNS.16–20 Such an increased
sympathetic tone may be a consequence of hypothalamic
changes, with an observed shift from corticotropin-releasing
hormone (CRH) to vasopressin, which has been demon-
strated in experimental arthritis.21 However, none of these
studies investigated the tone of the HPA axis in parallel.
Thus, a possible preponderance of one system over the other
was not investigated.
Why might it be important that the activity of the HPA axis
and the SNS are up regulated in parallel, and what would
happen if uncoupling of these axes appears? Release of
cortisol is typically coupled to release of norepinephrine,
which leads to stronger signalling through the b adrenocep-
tor; several studies have shown cooperation of cortisol and
norepinephrine at a molecular level.22–29 This permissive effect
of cortisol is due to b adrenoceptor up regulation and
stabilisation of the cyclic AMP (cAMP)/protein kinase A/
cAMP responsive element binding protein signalling path-
way.30 In patients with asthma, this has led to a more
effective combination treatment with local glucocorticoids
and local b adrenergic agents than either substance alone.31 32
Thus, it seems that instant coupling of the two stress axes
and their mediators is important for cooperative effects.
Cooperation may be important in chronic inflammatory
diseases to efficiently down regulate inflammation in the
periphery.33
Abbreviations: ACR, American College of Rheumatology; ACTH,
adrenocorticotropic hormone; CRH, corticotropin-releasing hormone;
HPA, hypothalamic-pituitary-adrenal; HS, healthy subjects; IL,
interleukin; NPY, neuropeptide Y; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus; SLEDAI, SLE Disease Activity Index; SNS,
sympathetic nervous system; TNF, tumour necrosis factor
* These authors contributed equally.
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This study aimed at investigate the tone of the SNS in
patients with SLE and RA by using neuropeptide Y (NPY), the
relatively stable sympathetic co-transmitter of norepinephr-
ine. NPY is an excellent indicator of sympathetic activity,34
which is more stable and has a significantly longer half life in
plasma.35 The correlation between NPY and norepinephrine
release has been demonstrated in obstructive sleep apnoea
syndrome,36 experimental stress,37 hypertension,38 surgery,39
hypoxia,40 and exercise.35 It is important to mention that the
characteristics of norepinephrine and NPY release are not
always identical: Norepinephrine is released at low exercise
levels, whereas NPY is released at higher exercise levels.34
This reflects the differential release of norepinephrine and
NPY from nerve terminals because norepinephrine is released
at low stimulation frequencies, whereas norepinephrine and
NPY are released together at higher stimulation frequencies.41
Furthermore, because NPY is produced in the sympathetic
neurone in paravertebral ganglia it needs to be transported to
the peripheral nerve ending. Thus, the availability of NPY, in
contrast with locally produced norepinephrine, depends on
production in the neuronal soma and the transport rate.42
However, when NPY is increased its most important source is
the sympathetic nerve terminal.
To our knowledge, NPY has never been investigated in the
serum or plasma of patients with RA and SLE. In parallel
with the SNS, we studied the HPA axis tone focusing on
ACTH and cortisol. Because administration of prednisolone to
healthy subjects increases the SNS tone,20 we analysed
separately patients with and without prior prednisolone
treatment. Furthermore, in patients with RA, we investigated
the effect of 12 weeks of anti-tumour necrosis factor (TNF)
treatment with adalimumab on NPY serum levels.
PATIENTS AND METHODS
Patients, anti-TNF treatment, and healthy subjects
We enrolled 32 white patients with SLE according to the
criteria of the American College of Rheumatology (ACR).43
Clinical activity in these patients was assessed by the SLE
Disease Activity Index (SLEDAI). To study patients with
another chronic inflammatory disease simultaneously, we
included 62 white patients with diagnosed RA fulfilling the
ACR criteria.44 Clinical variables of disease activity included
the number of swollen and tender joints and erythrocyte
sedimentation rate. Table 1 shows the basic characteristics of
both disease groups, including their treatment. None of the
patients without prednisolone received glucocorticoids dur-
ing a period of 6 months before study entry, whereas patients
with prednisolone had stable treatment over several weeks
before study entry.
Some patients with RA (16 with and 16 without parallel
prednisolone) were treated with adalimumab (Abbott SpA,
Campoverde di Aprilia, Italy) according to the inclusion
criteria of the adalimumab Research in Active RA study
(ReAct). These patients with RA received additional metho-
trexate (stable throughout this study) but no other immu-
nosuppressive drugs. Patients were assigned to receive single
self injections of adalimumab 40 mg subcutaneously every
other week. Efficacy assessments demonstrated excellent
response according to ACR and EULAR response criteria
(data not shown; see Atzeni et al45). A baseline, blood sample
was taken 1–2 weeks before the start of adalimumab
treatment. Anti-TNF antibodies were infused on weeks 0, 2,
4, 6, 8, 10, and 12. These patients were clinically investigated
and blood was drawn at baseline, and at weeks 2, 6, and 12.
For comparison, 65 white healthy subjects (HS) were
recruited, and their health status verified by a 33 item
questionnaire, as previously described.46 Fertile women (HS
and patients) were not taking contraceptives and were in the
early to mid-follicular phase of the menstrual cycle. Owing to
the different ages and sex distribution in the disease groups,
subgroup analyses were carried out in order to compare the
different groups of patients with HS. The subgroups were
matched according to age and sex (table 1). Because serum
levels of adrenal hormones are largely independent of sex,
male and female subjects were not further separated into
subgroups.
The study was approved by the ethics committee of the
University Hospital of Regensburg, Germany, and for the
adalimumab study, approval was obtained from the ethics
committee of L Sacco University Hospital, Italy.
Laboratory variables
In all subjects, blood was drawn between 08:00 and 10:00 in
the morning when the patients visited the outpatient clinic.
The blood was immediately centrifuged and serum or plasma
was stored at 280 C˚. We used radioimmunometric assays for
the quantitative determination of serum levels of NPY (Euro-
Diagnostica AB, Malmo¨, Sweden, via IBL, Hamburg,
Table 1 Basic characteristics of healthy subjects and patients with systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA)
Characteristics SLE
HS
RA
HS
(match SLE) (match RA)
Number 32 42 62 23
Age (years) 38.1 (2.1) 37.1 (1.5) 57.7 (1.7) 51.5 (0.8)
Sex, female/male (%) 24/8 (75/25) 25/17 (60/40) 52/10 (84/16) 12/11 (52/48)
Disease duration (years) 8.0 (1.5) NA 9.7 (1.0) NA
SLEDAI 10.9 (1.5) NA NA NA
Tender joints NA NA 9.0 (0.6) NA
Swollen joints NA NA 7.5 (0.6) NA
ESR (mm/1st h) 25.0 (3.3) NM 27.7 (2.4) NM
Drug
Prednisolone, No (%) 20 (63) NA 34 (55) NA
Prednisolone/day (mg) 9.4 (3.4) NA 4.3 (0.9) NA
NSAID, No (%) 13 (41) NA 38 (62) NA
Methotrexate, No (%) 2 (6) NA 43 (69) NA
Azathioprine, No (%) 12 (38) NA 0 (0) NA
Anti-TNF treatment, No (%) 0 (0) NA 38 (61) NA
Leflunomide, No (%) 0 (0) NA 8 (13) NA
Cyclophosphamide, No (%) 2 (6) NA 0 (0) NA
Hydroxychloroquine, No (%) 3 (9) NA 4 (6) NA
Sulfasalazine, No (%) 0 (0) NA 2 (3) NA
Data are given as means (SEM)unless stated otherwise.
ESR, erythrocyte sedimentation rate; NA, not applicable; NM, not measured; SLEDAI, SLE Disease Activity Index.
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Germany; detection limit: 6 pmol/l). Although the behaviour
of plasma ACTH and serum cortisol is known in patients with
SLE and RA, we measured these hormones to calculate ratios
of serum NPY/plasma ACTH and serum NPY/serum cortisol.
These ratios should give an impression of the interrelation of
the two hormones included. We used a radioimmunometric
assay for the quantitative determination of serum levels of
cortisol (Coulter Immunotech, Marseilles, France, via IBL;
detection limit: 10 nmol/l) and an enzyme immunoassay to
detect plasma ACTH (Sangui BioTech, Inc, California, USA,
via IBL; detection limit: 0.1 pmol/l). For all assays, intra-
assay and interassay coefficients of variation were below
10%.
Presentation of data and statistical analysis
The data are given as box plots with the 5th, 10th, 50th
(median), 90th, and 95th centiles. Group medians were
compared by the non-parametric Mann-Whitney test, corre-
lations were calculated by Spearman rank correlation
analysis (SPSS/PC, version 11.5, SPSS Inc, Chicago, USA).
A decrease or increase of a variable over time (during
adalimumab treatment) was tested by the non-parametric
Friedman test (SPSS). A value of p,0.05 was the level of
significance.
RESULTS
NPY serum levels in patients with SLE, RA, and in HS
Figure 1 demonstrates higher NPY serum levels in patients
with SLE than in HS, irrespective of prednisolone treatment
(fig 1A). In RA, only patients with prior prednisolone had
increased NPY serum levels in comparison with healthy
subjects (fig 1B). Because age matched healthy subjects had
relatively high NPY serum levels, no difference was noted in
comparison with patients with RA without prednisolone
treatment (fig 1B).
The results of increased NPY levels in patients with RA
treated with prednisolone prompted us to study the inter-
relation of the daily prednisolone dose and NPY serum levels.
Clearly, the prednisolone dose correlated with NPY serum
levels in patients with RA but not in patients with SLE
(figs 1C and D). However, plasma NPY levels did not correlate
with typical markers of disease activity such as tender joint
score in RA (without prednisolone: RRank = 0.111, NS; with
prednisolone: RRank = 0.227, NS), swollen joint score in RA
(without prednisolone: RRank =20.010, NS; with predniso-
lone: RRank = 0.356, p = 0.088), and SLEDAI in SLE (without
prednisolone: RRank = 0.023, NS; with prednisolone:
RRank = 0.044, NS).
Plasma NPY levels did not differ between male and female
patients with or without prednisolone (data not shown).
Therapeutic agents such as non-steroidal anti-inflammatory
drugs, methotrexate, azathioprine, and leflunomide did not
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Figure 1 Serum NPY in HS, patients with SLE and RA. (A) Comparison
of HS and patients with SLE. (B) Comparison of HS and patients with RA.
For panels (A) and (B) data are given as box plots with the 5th, 10th,
50th (median), 90th, and 95th centiles. (C) and D) Interrelation of daily
prednisolone dose and serum NPY levels in prednisolone treated patients
with SLE (C) and RA (D). The linear regression line, the rank correlation
coefficient and its p value are given.
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Figure 2 Relation of NPY and plasma ACTH in HS, patients with SLE,
and RA. (A) and (B) Plasma levels of ACTH. (C) and (D) Ratio of serum
NPY and plasma ACTH. All data are given as box plots with the 5th,
10th, 50th (median), 90th, and 95th centiles.
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influence serum NPY levels in patients with RA or SLE (data
not shown).
Relation of NPY serum levels and HPA axis hormones
To study the relation between NPY and HPA axis hormones,
molar ratios of NPY/ACTH and NPY/cortisol were calculated.
These ratios express a possible preponderance of the SNS over
the HPA axis or vice versa. As expected, patients with SLE
and RA with prior prednisolone demonstrated decreased
ACTH levels (figs 2A and B). In addition, patients with RA
without prior prednisolone treatment also had decreased
ACTH levels in comparison with healthy subjects (fig 2B).
The ratio of NPY/ACTH was significantly higher in patients
with SLE and RA than in healthy controls, irrespective of
prior prednisolone treatment (figs 2C and D). In patients
with RA, prednisolone treatment increased this particular
ratio (fig 2D).
For cortisol, patients with SLE demonstrated decreased
serum levels, irrespective of prior prednisolone treatment
(fig 3A). In RA, only those patients with prior prednisolone
treatment had decreased cortisol serum levels (fig 3B). The
ratio of NPY/cortisol was increased in both SLE patient
groups, irrespective of prednisolone treatment (fig 3C).
Additionally, patients with SLE treated with prednisolone
had a higher increased ratio of NPY/cortisol than untreated
patients (fig 3C). In RA, only patients with prior prednisolone
treatment had an increased ratio of NPY/cortisol in compar-
ison with HS (fig 3D).
The above-mentioned ratios did not differ between male
and female patients with or without prednisolone (data not
shown). Therapeutic agents such as non-steroidal anti-
inflammatory drugs, methotrexate, azathioprine, and leflu-
nomide did not influence serum NPY levels in patients with
RA or SLE (data not shown).
Influence of anti-TNF treatment in RA on NPY serum
levels
Using the Friedman test statistics, 12 weeks of anti-TNF
treatment did not change NPY serum levels, irrespective of
prednisolone treatment (fig 4). Again it is obvious that
patients with RA with prednisolone had increased serum
NPY levels in comparison with untreated patients with RA
(fig 4). In addition, neither the ratio of serum NPY/plasma
ACTH nor the ratio of serum NPY/serum cortisol changed
during 12 weeks of anti-TNF treatment (data not shown).
DISCUSSION
Using NPY as a reliable read-out measure of the SNS activity,
we were able to demonstrate an increased SNS outflow in
relation to the HPA axis tone in all patients with SLE and in
patients with RA treated with prednisolone. For the ratio of
serum NPY/plasma ACTH, also patients with RA without
prednisolone demonstrated a preponderance of the SNS over
the HPA axis.
Several studies have demonstrated an increased sympathetic
tone in patients with chronic inflammatory diseases.16–20
However, none of these studies investigated the tone of the
HPA axis in parallel. Thus, the preponderance of one system
over the other was not investigated. In a recent study in patients
with Crohn’s disease and ulcerative colitis, we observed a very
similar phenomenon of a preponderance of the SNS over the
HPA axis47: serum NPY levels were increased, whereas serum
cortisol levels were normal or decreased. We called this
phenomenon uncoupling of the SNS and HPA axis in order to
emphasise the loss of cooperative activities of these two
endogenous response systems.47 This present study supports
uncoupling of the two main response axes in patients with SLE
and RA. Uncoupling is enhanced in prednisolone treated
patients because prednisolone stimulates the SNS and inhibits
the HPA axis even in healthy subjects.20 Interestingly, 12 weeks
of anti-TNF treatment in patients with RA slightly reduced
raised NPY serum levels and SNS dominance. Thus, it seems
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that uncoupling is enduringly imprinted, and it is obvious that
TNF is not the sole and main factor responsible for this
phenomenon.
For patients without prednisolone treatment, it is interest-
ing that the uncoupling phenomenon is obvious in our young
patients with SLE but not similarly in the older patients with
RA. Similarly, our recent studies in young patients with
inflammatory bowel disease demonstrated the uncoupling
phenomenon in patients without prednisolone.47 It may well
be that aging has an influence on the uncoupling phenom-
enon, which has been demonstrated in HS focusing on serum
cortisol and plasma norepinephrine.48 In this latter study,
however, plasma NPY levels did not similarly increase during
aging, which was shown for plasma norepinephrine, con-
firming an earlier study.49 Thus, it seems that in older
subjects NPY is not produced to a similar extent as
norepinephrine.48 From this point of view, it may well be
that older patients with RA without prednisolone do not
demonstrate high levels of NPY, though norepinephrine
might have been increased. In older patients, NPY may not be
the ideal measure when SNS activity is only increased to a
small extent. In our study we did not measure norepinephr-
ine because we expected a strong bias due to a prolonged
storage period (norepinephrine is much more labile than
NPY).
Coupling of the SNS and HPA axis is important because it
supports the b adrenergic and glucocorticoid receptor path-
ways,22–29 which would lead to stronger cooperative effects
than using one system alone. Cooperative activity of both
axes is observed in asthmatic patients who use local
glucocorticoids and local b2 adrenergic agents.
31 32 In these
patients, cooperation increases the bronchodilatory effect of
each substance alone. A similar cooperation can be observed
in patients with septic shock50: combined treatment with
norepinephrine and cortisol leads to improved circulation and
blood pressure. Similarly, a cooperative effect of cortisol and
norepinephrine is also found in patients with RA (see below).
In patients with chronic inflammatory diseases, a relative loss
of HPA axis hormones in relation to proinflammatory
cytokines may lead to deficient vasopressive activity of SNS
neurotransmitters, which may consequently lead to up
regulation of the SNS tone. This may counterbalance the
loss of cortisol in the presence of increased circulating
vasodilators such as nitric oxide, TNF, and others.
These SNS changes may be supported by the observed
hypothalamic shift from initially high CRH expression to
chronically increased vasopressin expression, which has been
demonstrated during experimental arthritis.21 This shift to
increased vasopressin production can also be viewed as a sign
of an increased sympathetic tone in relation to the HPA axis
(CRH) because increased vasopressin levels would support
the SNS in stabilising blood pressure. Apart from effects on
bronchodilation and circulation, cooperation may also lead to
stronger anti-inflammatory effects. In addition, disease
related factors such as depression, chronic pain, weight gain,
and others may add to the uncoupling phenomenon.
In patients with RA, we recently demonstrated anti-
inflammatory cooperation of norepinephrine and cortisol33:
combined administration of norepinephrine and cortisol to
cultured mixed synovial cells led to a stronger reduction of
TNF, IL8, and IL6 secretion than the use of each substance
alone. Furthermore, patients with RA with prednisolone
treatment and presence of synovial sympathetic nerve fibres
had decreased histological markers of synovial inflammation
in comparison with patients without prednisolone treatment
or without sympathetic innervation.33 Thus, high levels of
mediators of the SNS together with cortisol at the local site of
inflammation may be favourable factors which dampen
inflammation.
However, it has been demonstrated that sympathetic
innervation is decreased in inflammatory processes such as
in the spleen of lupus lpr/lpr mice,51 in the synovium of
patients with RA,52 and in inflamed islets of diabetic rats.53
Thus, an increased systemic tone of the SNS probably would
not lead to increased local sympathetic neurotransmitters
because sympathetic nerve fibres are lost. In such a situation,
local concentrations of sympathetic neurotransmitters are
low, which would support the proinflammatory process via a
adrenoceptors (reviewed by Straub et al54). Loss of sympa-
thetic nerve fibres and low levels of cortisol and androgens
would lead to a proinflammatory microenvironment in
inflamed tissue. In support of this notion, it has been
repeatedly demonstrated that a higher SNS tone increases
circulating leucocytes, such as monocytes, NK cells, and
neutrophils.55 56 Probably, this has been evolutionarily con-
served in order to support the immune system in the very
early phase of a systemic inflammatory response (help for the
innate immune system). However, in patients with chronic
inflammatory diseases such a stimulation of leucocyte
migration and redistribution is probably unfavourable.
In conclusion, an increased SNS tone in the presence of a
defective HPA axis probably supports the continuing inflam-
matory process. In addition, an increased SNS tone would
support atherosclerosis in patients with chronic inflamma-
tory diseases. These observations may stimulate rheumatol-
ogists to treat patients with centrally acting drugs in order to
inhibit enhanced SNS outflow.
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